Neonatal encephalopathy or new therapy

Neonatal encephalopathy or new therapy

February 1, 2019 Source: Health News Network Author: Yu Wen Su

Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];

Recently, the Sichuan Provincial Stem Cell Bank National (Local) Joint Engineering Laboratory and the West China Second Hospital of Sichuan University jointly published papers in the Dutch Journal of Behavioral Brain Research. Related studies have shown that transplantation of cord blood mononuclear cells (CB-MNCs) and umbilical cord mesenchymal stem cells (UC-MSCs) in rat models of hypoxic-ischemic injury can promote spatial memory recovery and reduce cell death. Death, reducing the number of astrocytes. Studies have shown that this is a good alternative to neonatal hypoxic ischemic encephalopathy (HIE).

Neonatal hypoxic ischemic encephalopathy is a neurological disease of high morbidity and mortality worldwide, with approximately 1.5 out of every 1,000 full-term newborns. At present, the treatment of the disease is mainly symptom support therapy, such as the treatment of moderate to severe HIE premature infants by hypothermia, but can not repair the damaged cranial nerves, nor promote nerve regeneration.

Stem cells have the potential to self-renew and multi-directionally differentiate into multiple cell types and play a key role in tissue repair regeneration. Mesenchymal stem cells derived from tissues such as the umbilical cord have good safety, high proliferative potential, self-renewal, and significant immunomodulatory properties, and have been widely used in preclinical studies and clinical trials of various diseases. Previous preclinical studies have shown that both umbilical cord mesenchymal stem cells and cord blood mononuclear cells can improve symptoms after hypoxia-ischemia, but it has not been proven which cell type has better efficacy.

The researchers transplanted PKH26-labeled umbilical cord mesenchymal stem cells and cord blood mononuclear cells into neonatal rats with hypoxic-ischemic brain damage. The number of apoptotic cells in the brain was assessed by TUNEL labeling. Myelin regeneration and gliosis were studied by immunohistochemical method of myelin basic protein and glial fibrillary acidic protein, respectively. Morris water maze was used to detect animal learning. And memory ability.

Studies have found that transplantation of umbilical cord mesenchymal stem cells or cord blood mononuclear cells after hypoxia-ischemia can reduce astrocyte proliferation, prevent striatum neuron loss, and significantly improve brain function after 28-day recovery period. In addition, treatment with cord blood mononuclear cells increases the proportion of mature oligodendrocytes and promotes remyelination. Dr. Yang Chao, a senior researcher at the Stem Cell and Regenerative Medicine Research Center of the National (Local) Joint Engineering Laboratory of Sichuan Stem Cell Bank, believes that the administration of umbilical cord mesenchymal stem cells or cord blood mononuclear cells after neonatal hypoxic-ischemic injury can significantly improve brain function. Promote the recovery of neurobehavioral behavior.

X Ray Lead Goggles

X Ray Lead Glasses,Medical Ray Lead Glasses,X Ray Lead Protective Eyewears,X-Ray Radiation Leaded Protective Eyewear,Protective Leaded Eyewear

Longkou Kangxie Medical Instrument Co., Ltd , https://www.kangxiemedical.com